BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, February 24, 2026
Home » Authors » Elise Mak

Elise Mak

Articles

ARTICLES

Hong Kong PolyU collaborates with European institutions on R&D platform

March 19, 2018
By Elise Mak
HONG KONG – Hong Kong Polytechnic University (PolyU) is partnering with two European institutions to establish a life sciences and engineering R&D platform to spearhead applied research.
Read More

JW Therapeutics draws $90M, new investors in series A round for CAR T candidate

March 13, 2018
By Elise Mak

HONG KONG – JW Therapeutics (Shanghai) Co. Ltd. raised $90 million in a series A financing for the development of its first CD19-directed investigational cancer therapy, JWCAR-029. Investors include prominent names such as Singapore-based Temasek, Sequoia Capital China and Yuanming Capital.


Read More

Multinational companies see opportunity as IVD market set to triple in China

March 12, 2018
By Elise Mak

JW Therapeutics draws $90M, new investors in series A round for CAR T candidate

March 12, 2018
By Elise Mak
HONG KONG – JW Therapeutics (Shanghai) Co. Ltd. raised $90 million in a series A financing for the development of its first CD19-directed investigational cancer therapy, JWCAR-029. Investors include prominent names such as Singapore-based Temasek, Sequoia Capital China and Yuanming Capital.
Read More

Golden Meditech licensed for genetic testing in China

March 9, 2018
By Elise Mak

Trial recruitment easier in China? Not so fast, according to analysis

March 6, 2018
By Elise Mak

HONG KONG – The sheer speed of growth of the biotech and med-tech industries in China has easily outpaced the development of regulation and has led to concerns that too many of the ballooning number of clinical trials in the country fail to meet enrollment targets.


Read More

Trial recruitment easier in China? Not so fast, according to analysis

March 1, 2018
By Elise Mak

Trial recruitment easier in China? Not so fast, according to analysis

March 1, 2018
By Elise Mak
HONG KONG – The sheer speed of growth of the biotech and med-tech industries in China has easily outpaced the development of regulation and has led to concerns that too many of the ballooning number of clinical trials in the country fail to meet enrollment targets.
Read More

Pre-revenue biotech startups go public in Hong Kong under new listing rules

Feb. 28, 2018
By Elise Mak
HONG KONG – Biotech companies that have not yet generated any revenue can seek listing on the Main Board of the Hong Kong Stock Exchange (HKEX). The exchange proposed the new policy Friday as part of the effort to lure more firms to go public, bolstering Hong Kong's biotech development.
Read More

Pre-revenue biotech startups get green light to go public in Hong Kong

Feb. 27, 2018
By Elise Mak
View All Articles by Elise Mak

Popular Stories

  • Today's news in brief

    BioWorld
  • IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

    BioWorld Science
    Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
  • Illustration of head with maze that is missing parts

    Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

    BioWorld Science
    Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
  • Pill in immersive interface

    New mechanism of action identified for QC-6352

    BioWorld Science
    QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
  • Illustration of brain and antibodies

    VST Bio’s VB-001 is neuroprotector after stroke

    BioWorld Science
    At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing